Overzicht Proefschriften
Tips in using the search/filter fieldsDisplaying 51-100 of 278 results.
Titel | Promovendus | Promotor 1 | Promotor 2 | Copromotor 1 | Copromotor 2 | Universiteit | Promotiejaar | Trefwoorden |
---|---|---|---|---|---|---|---|---|
Optimizing protease inhibitor-based antiretroviral therapy for HIV-1 infected Thai adults and children | Lugt J. van der, dr. | Lange J.M.A., prof. dr. | Ananworanich J., dr. | Burger D.M., prof. dr. | Universiteit van Amsterdam (UvA) | 2010 | Antiretroviral; HIV; Pharmacokinetics; Clinical pharmacology; therapeutic drug monitoring | |
Human pharmacology of current and novel gaba(a)-ergic treatments for anxiety | Chen X., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Jacobs G.E., dr. | Universiteit Leiden (UL) | 2017 | Anxiety Human pharmacology GABA-ergic treatment | |
Development and use of biomarkers in clinical development of new therapies for chronic airway disease | Zuiker R.G.J.A | Burggraaf J., prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2016 | Asthma COPD Biomarkers Allergen challenges Inflammation | ||
Towards better treatment outcomes in childhood asthma | Koster E.S., PhD | Raaijmakers J.A.M., prof. dr. | Maitland-van der Zee A.H., prof. dr. | Universiteit Utrecht (UU) | 2011 | Asthma; Children; Treatment Outcomes; Epidemiology; | ||
Individualized dosing of serotherapy in allogeneic hematopoietic cell transplantation | Admiraal R., PhD | Knibbe C.A.J., prof. dr. | Boelens J.J., dr. | Bredius R.G.M., dr. | Universiteit Leiden (UL) | 2017 | ATG; Population PK; Stem cell transplantation; Immune reconstitution; Serotherapy; | |
Future drugs in atherosclerotic cardiovascular disease | Poelgeest E.P van | Burggraaf J., prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2018 | Atherosclerosis Systemic inflammation Hypercholesterolemia PCSK9 inhibitor TLR4 sinaling Acute kidney injury Endothelial dysfunction Human endotoxemia model Ex vivo LPS challenge test Invivo LPS challenge test | ||
Implications of the cardiomyocyte stress response on protein homeostasis in atrial fibrillation | Wiersma M., PhD | Henning R.H., prof. dr. | Brundel B.J.J.M., dr. | Rijksuniversiteit Groningen (RUG) | 2016 | Atrial fibrillation; | ||
Targeting proteostasis in atrial fibrillation | Zhang D., PhD | Henning R.H., prof. dr. | Brundel B.J.J.M., dr. | Rijksuniversiteit Groningen (RUG) | 2015 | Atrial fibrillation; Modelling-&-simulations; | ||
Loss of proteostasis as a substrate for Atrial Fibrilation. | Meijering R.A.M., PhD | Henning R.H., prof. dr. | Brundel B.J.J.M., dr. | Rijksuniversiteit Groningen (RUG) | 2014 | Atrial fibrillation; Proteostasis; | ||
From data to models : reducing uncertainty in benefit risk assessment : application to chronic iron overload in children | Bellanti F., PhD | Danhof M., prof. dr. | Della Pasqua O.E., dr. | Universiteit Leiden (UL) | 2015 | Benefit-risk assessment; Paediatrics; Iron chelations; PK-PD modelling; Modelling-&-simulations; Multi-criteria-decision-analysis; Iron-overload; Deferiprone; Deferoxamine; | ||
Benefits and risks for the individual : anticoagulation for patients with atrial fibrillation | Ham H.A. van den, PhD | Leufkens H.G.M., prof. dr. | Klungel O.H., prof. dr. | Staa T.J. van, prof. dr. | Universiteit Utrecht (UU) | 2016 | Benefit-risk balance; Atrial fibrillation; Oral anticoagulants; Observational studies; Individuals; | |
Pharmacovigilance of biologicals : dynamics in post-approval safety learning | Vermeer N.S., PhD | Leufkens H.G.M., prof. dr. | Egberts A.C.G., prof. dr. | Bruin M.L. de, prof. dr. | Straus S.M.J.M., dr. | Universiteit Utrecht (UU) | 2015 | Biologicals; Biosimilars; Pharmacovigilance; Adverse drug reactions; Regulatory science; Traceability; Risk management plan; |
Monitoring patients using clozapine | Man W.H., PhD | Egberts A.C.G., prof. dr. | Solinge W.W. van, prof. dr. | Wilting I., dr. | Heerdink E.R., dr. | Universiteit Utrecht (UU) | 2018 | Biomarkers; Adherence; Monitoring; Sialorrhea; Inflammation; Glycopyrrolate; Schizophrenia; Antipsychotics; Pharmacovigilance; |
Novel biomarker panels in diabetic kidney disease: predicting disease progression and response to therapy, and monitoring drug effect | Pena M.J., PhD | Zeeuw D. de, prof. dr. | Lambers Heerspink H.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2015 | Biomarkers; Diabetes mellitus; Kidney; | ||
Sticky & Dirty Proteins- or on the poorly characterised, peculiar, pharmacokinetic and immunostimulatory aspects of biopharmaceuticals | Reijers J.A.A. | Burggraaf J., prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2018 | Biopharmaeuticals Biologics Clinical Pharmacology Pharmacokinetics Adverse immunostimulation Immunotoxicity Drug impurity Drug contamination Monoclonal antibody | ||
Unravelling the link between diabetes, insulin treatment and breast cancer | Bronsveld H.K., PhD | Boer A. de, prof. dr. | Bruin M.L. de, prof. dr. | Schmidt M.K., dr. ir. | Universiteit Utrecht (UU) | 2017 | Breast cancer; Risk factors; Diabetes mellitus; Insulin growth factor; Diabetes treatment; | |
New insights into the role of breast cancer resistance protein in endocrine and metabolic processes | Dankers A.C.A., PhD | Russel F.G.M., prof. dr. | Sweep C.G.J., prof. dr. | Masereeuw R., prof. dr. | Radboud Universiteit (RU) | 2014 | Cancer; Breast cancer; | |
Bioanalysis and clinical pharmacology of tamoxifen in breast cancer | Jager N.G.L., PhD | Beijnen J.H., prof. dr. | Schellens J.H.M., prof. dr. | Rosing H., dr. | Universiteit Utrecht (UU) | 2014 | Cancer; Clinical pharmacology; | |
Clinical pharmacology of genotype-directed anticancer therapy - Towards rational combination strategies | Geel R.M.J.M. van, PhD | Schellens J.H.M., prof. dr. | Beijnen J.H., prof. dr. | Huitema A.D.R., prof. dr. | Cats A., dr. | Universiteit Utrecht (UU) | 2016 | Cancer; Genetics; BRAF; Colorectal cancer; Combination therapy; p53-deficient ovarian cancer; AZD1775; Treatment individualization; |
The role of pharmacogenetics in osteosarcoma | Hagleitner M.M., PhD | Hoogerbrugge P.M., prof. dr. | Guchelaar H.J., prof. dr. | Loo D.M.W.M. te, dr. | Coenen M.J.H., dr. | Radboud Universiteit (RU) | 2015 | Cancer; Osteosarcoma; Pharmacogenetics; Genetics; Chemotherapy; |
Cardiovascular, renal and thyroid toxicity during angiogenesis inhibition: a translational approach | Kappers M.H.W., PhD | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2011 | Cancer; Pharmacology; Antihypertensive drugs; | |||
Novel approaches in clinical development of cannabinoid drugs | Klumpers L.E., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2014 | Cannabinoids; THC; CB1 antagonists; Pharmacokinetics; Clinical pharmacology; Pharmacodynamics; Feeling high; PK-PD modelling; Resting state FMRI; Rimonabant; | ||
The aging cardiovascular system: genetic and epigenetic determinants of vascular outcomes and cardiometabolic risk | Portilla Fernández E | Danser A.H.J., prof. dr. | Ikram MA, prof.dr. | Roks A.J.M., dr. | Dehghan A, dr. | Erasmus Universiteit Rotterdam (EUR) | 2019 | Cardiac aging; Cardiovascular disease; Genetics; Epidemiology; Epigenetics; Vascular reactivity; Pharmacology; |
Techniques to improve neurological outcome after cardiac surgery | Kok W.F., PhD | Henning R.H., prof. dr. | Absalom A.R., prof. dr. | Scheeren T.W.L., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Cardiac surgery; Clinical pharmacology; Neurological outcome; | |
Vascular reactivity in cardiopulmonary bypass | Samarska I., PhD | Henning R.H., prof. dr. | Struys M.M.R.F., prof. dr. | Buikema J.H., dr. | Epema A.H., dr. | Rijksuniversiteit Groningen (RUG) | 2011 | Cardiopulmonary bypass; Vascular reactivity; |
Biomarkers as assessment of drug efficacy in cardiovascular disease | Smink P.A., PhD | Zeeuw D. de, prof. dr. | Lambers Heerspink H.J., prof. dr. | Bakker S.J.L., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2013 | cardiovascular disease biomarkers drug efficacy | |
The role of aldosterone and aldosterone blockade in hypertension | Jansen P.M., PhD | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2013 | Cardiovascular disease; Antihypertensive drugs; Pharmacology; | |||
Multimodality ImAging of Cardiovascular Dysfunction: Risk factors, diagnostics and treatment options | Thiel B.S. van, PhD | Kanaar R., prof. dr. | Danser A.H.J., prof. dr. | Essers J., dr. | Pluijm I. van der, dr. | Erasmus Universiteit Rotterdam (EUR) | 2017 | Cardiovascular disease; Imaging; Aging; Risk factors; Diagnostics; Treatment options |
Vascular aging from DNA damage to protection | Ďurik M., PhD | Danser A.H.J., prof. dr. | Roks A.J.M., dr. | Erasmus Universiteit Rotterdam (EUR) | 2012 | Cardiovascular disease; Pharmacology; | ||
Cardiac aldosterone: origin and effects | Chai W., dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2005 | Cardiovascular disease; Pharmacology; | |||
Angiotensin II-induced vasodilation: role of bradykinin, NO and endothelium-derived hyperpolarizing factors | Batenburg W.W., dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2005 | Cardiovascular disease; Pharmacology; | |||
Characterization of vascular 5-hydroxytryptamine, adrenergic and CGRP receptors in relation to migraine | Mehrotra S., dr. | Saxena P.R., prof. dr. | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2006 | Cardiovascular disease; Pharmacology; | |
Vascular pharmacology of migraine and preeclampsia: Problems of the fair sex | Gupta S., dr. | Saxena P.R., prof. dr. | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2006 | Cardiovascular disease; Pharmacology; | |
The (pro)renin receptor: moving away from prorenin? | Lu X., PhD | Danser A.H.J., prof. dr. | Meima M.E., dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Cardiovascular disease; Pharmacology; Prorenin; | ||
(Pro)renin revisited: new insights from studies in mast cells | Krop M., dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2009 | Cardiovascular disease; Pharmacology; Prorenin; | |||
Unraveling the complexities of the renin-angiotensin system: from ACE to renin inhibition | Esch J.H.M. van, dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2008 | Cardiovascular disease; Pharmacology; Renin-angiotensin system; | |||
Multimodality ImAging of Cardiovascular Dysfunction: Risk Factors, Diagnostics and Treatment Options | Thiel B.S. van, PhD | Kanaar R., prof. dr. | Danser A.H.J., prof. dr. | Essers J., dr. | Pluijm I. van der, dr. | Erasmus Universiteit Rotterdam (EUR) | 2017 | Cardiovascular disease; Risk factors; Treatment options; |
Carotid artery contrast enhanced ultrasound | Kate G.L. ten, PhD | Sijbrands E.J.G., prof. dr. | Danser A.H.J., prof. dr. | Schinkel A.F.L., Dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Cardiovascular disease; Vascular reactivity; | |
Endothelial dysfunction in cardiovascular disease | Heuvel M. van den, PhD | Duncker D.J.G.M., Prof.dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2018 | Cardiovascular disease; Vascular reactivity; Cholesterol; | ||
DNA Damage-related Vascular Dysfunction: Pathways and Interventions | Bautista-Niño P.K., PhD | Danser A.H.J., prof. dr. | Franco Duran O.H., Prof.dr. | Roks A.J.M., dr. | Ghanbari M., dr. | Erasmus Universiteit Rotterdam (EUR) | 2017 | Cardiovascular disease; Vascular reactivity; DNA damage; |
Experimental focal cerebral ischemia: optimalisation of models and therapeutic interventions | Shanbhag N.C., PhD | Henning R.H., prof. dr. | Schilling L., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2016 | Cerebral ischemia; | ||
COMPARE: Care in Oncolytic Medication surveillance:Pharmacovigilance, Acceptability, Risks and Events | Oijen B.P.C. van, dr. | Schouten H.C., prof. dr. | Kuy P.H.M. van der, dr. | Janknegt R., PharmD PhD | Universiteit Maastricht (UM) | 2015 | Chemotherapy; Clinical pharmacology; Pharmaceutical care; | |
Risk factors and treatment of paediatric chronic diseases - Type 1 diabetes, asthma and allergy | Ahmadizar F., PhD | Boer A. de, prof. dr. | Maitland-van der Zee A.H., prof. dr. | Universiteit Utrecht (UU) | 2016 | Children; Diabetes mellitus; Allergy | ||
Comorbidities, complications and treatment of childhood obesity | Lentferink Y.E., PhD | Knibbe C.A.J., prof. dr. | Vorst M.M.J. van der, dr. | Universiteit Leiden (UL) | 2019 | Children; Obesity; Asthma; ADHD; Insulin resistance; Metformin; Cardiovascular diseases; Obese children; Arterial stiffness; Skin autofluorescence; | ||
Optimization of electronic prescribing in pediatric patients | Maat B., PhD | Egberts A.C.G., prof. dr. | Vught A.J. van, prof. dr. | Rademaker C.M.A., dr. | Bollen C.W., dr. | Universiteit Utrecht (UU) | 2014 | Children; Paediatrics; Electronic prescribing; |
Non-dispensing clinical pharmacists in general practice : training, implementation and clinical effects | Hazen A.C.M., PhD | Bouvy M.L., prof. dr. | Wit N.J. de, prof. dr. | Bont A.A. de, prof. dr. | Zwart D.L.M., dr. | Universiteit Utrecht (UU) | 2018 | Clinical pharmacist; General practice; Medication reviews; Polypharmacy; Hospitalization; Professional identity; |
Integrated assessment of neurocognitive, neurophysiological and pain processing in early clinical drug development | Amerongen G. van, PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Universiteit Leiden (UL) | 2020 | Clinical pharmacology Pharmacodynamics Pain Human pain models Cannabinoid GABA THC Multiple sclerosis (MS) | |
Drug-induced psychomimetic symptoms as a model for psychosis | Kleinloog-Fernández González H.D., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2014 | Clinical Pharmacology Psychotic Disorders Clinical Trial Drug evaluation Biological Models | ||
Making things easier: how to improve antiviral drug treatment for children | Bastiaans D.E.T., dr. | Burger D.M., prof. dr. | Radboud Universiteit (RU) | 2016 | Clinical pharmacology; Antiviral drug treatment; | |||
Clinical pharmacology of novel anticancer drug formulations | Stuurman F.E, PhD | Schellens J.H.M., prof. dr. | Beijnen J.H., prof. dr. | Universiteit Utrecht (UU) | 2013 | Clinical pharmacology; Cancer; |